SLC5A2 and hydrops fetalis: In patients with HF and type 2 DM, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-Reg) trial showed that empagliflozin, an SGLT-2 inhibitor decreased cardiovascular-related mortality compared to placebo (10.5% vs. 12.1%; hazard ratio 0.86, 95%CI 0.74-0.99 and p=0.04) [47].